Do analysts recommend ELOX or INCR?

Eloxx Pharmaceuticals currently has a consensus price target of $41.50, indicating a potential upside of 121.22%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Eloxx Pharmaceuticals is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eloxx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ELOX or INCR more profitable?

Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A InterCure N/A N/A N/A

Does the media refer more to ELOX or INCR?

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than InterCure. MarketBeat recorded 4 mentions for Eloxx Pharmaceuticals and 2 mentions for InterCure. InterCure's average media sentiment score of 0.93 beat Eloxx Pharmaceuticals' score of 0.57 indicating that InterCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InterCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ELOX or SCYX?

In the previous week, Eloxx Pharmaceuticals and Eloxx Pharmaceuticals both had 4 articles in the media. SCYNEXIS's average media sentiment score of 1.02 beat Eloxx Pharmaceuticals' score of 0.57 indicating that SCYNEXIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SCYNEXIS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is KPTI or ELOX more profitable?

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics -153.28% N/A -144.95% Eloxx Pharmaceuticals N/A N/A N/A

Does the media favor KPTI or ELOX?

In the previous week, Karyopharm Therapeutics had 8 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 12 mentions for Karyopharm Therapeutics and 4 mentions for Eloxx Pharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 0.57 beat Karyopharm Therapeutics' score of -0.03 indicating that Eloxx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ELOX or VERU more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A Veru N/A -47.58% -35.83%

Does the media favor ELOX or VERU?

In the previous week, Veru had 5 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 9 mentions for Veru and 4 mentions for Eloxx Pharmaceuticals. Veru's average media sentiment score of 0.95 beat Eloxx Pharmaceuticals' score of 0.57 indicating that Veru is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veru 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is ELOX or FLNA more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A Cassava Sciences N/A -58.78% -36.74%

Does the media favor ELOX or FLNA?

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 4 mentions for Eloxx Pharmaceuticals and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat Eloxx Pharmaceuticals' score of 0.57 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eloxx Pharmaceuticals (ELOX) Competitors

$18.76 -0.31 (-1.63%)

As of 08/14/2026 04:00 PM Eastern

Compare

ELOX vs. INCR, SCYX, KPTI, VERU, and FLNA

Should you buy Eloxx Pharmaceuticals stock or one of its competitors? Eloxx Pharmaceuticals's main competitors and comparable companies include InterCure (INCR), SCYNEXIS (SCYX), Karyopharm Therapeutics (KPTI), Veru (VERU), and Cassava Sciences (FLNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eloxx Pharmaceuticals compare to InterCure?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and InterCure (NASDAQ:INCR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Eloxx Pharmaceuticals currently has a consensus price target of $41.50, indicating a potential upside of 121.22%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Eloxx Pharmaceuticals is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Eloxx Pharmaceuticals has a beta of -1864.08, meaning that its stock price is 186,508% less volatile than the broader market. Comparatively, InterCure has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of InterCure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than InterCure. MarketBeat recorded 4 mentions for Eloxx Pharmaceuticals and 2 mentions for InterCure. InterCure's average media sentiment score of 0.93 beat Eloxx Pharmaceuticals' score of 0.57 indicating that InterCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InterCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eloxx Pharmaceuticals has higher earnings, but lower revenue than InterCure. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	2.04	-$5.99M	-$15.29	N/A
InterCure	$78.47M	0.67	-$10.37M	$0.03	32.00

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
InterCure	N/A	N/A	N/A

Summary

Eloxx Pharmaceuticals beats InterCure on 7 of the 13 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to SCYNEXIS?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Eloxx Pharmaceuticals has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Eloxx Pharmaceuticals' return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
SCYNEXIS	-41.79%	-44.15%	-32.61%

Eloxx Pharmaceuticals has higher earnings, but lower revenue than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	2.04	-$5.99M	-$15.29	N/A
SCYNEXIS	$20.60M	2.50	-$8.61M	-$2.09	N/A

Eloxx Pharmaceuticals has a beta of -1864.08, meaning that its share price is 186,508% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

In the previous week, Eloxx Pharmaceuticals and Eloxx Pharmaceuticals both had 4 articles in the media. SCYNEXIS's average media sentiment score of 1.02 beat Eloxx Pharmaceuticals' score of 0.57 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SCYNEXIS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Eloxx Pharmaceuticals currently has a consensus price target of $41.50, indicating a potential upside of 121.22%. SCYNEXIS has a consensus price target of $33.00, indicating a potential upside of 537.07%. Given SCYNEXIS's higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Eloxx Pharmaceuticals and SCYNEXIS tied by winning 7 of the 14 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Karyopharm Therapeutics currently has a consensus price target of $11.50, indicating a potential upside of 469.31%. Eloxx Pharmaceuticals has a consensus price target of $41.50, indicating a potential upside of 121.22%. Given Karyopharm Therapeutics' higher probable upside, equities research analysts plainly believe Karyopharm Therapeutics is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Eloxx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-144.95%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Karyopharm Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Eloxx Pharmaceuticals has a beta of -1864.08, meaning that its stock price is 186,508% less volatile than the broader market.

Eloxx Pharmaceuticals has lower revenue, but higher earnings than Karyopharm Therapeutics. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.31	-$196.04M	-$15.09	N/A
Eloxx Pharmaceuticals	$6.36M	2.04	-$5.99M	-$15.29	N/A

In the previous week, Karyopharm Therapeutics had 8 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 12 mentions for Karyopharm Therapeutics and 4 mentions for Eloxx Pharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 0.57 beat Karyopharm Therapeutics' score of -0.03 indicating that Eloxx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Karyopharm Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Karyopharm Therapeutics beats Eloxx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Veru?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

In the previous week, Veru had 5 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 9 mentions for Veru and 4 mentions for Eloxx Pharmaceuticals. Veru's average media sentiment score of 0.95 beat Eloxx Pharmaceuticals' score of 0.57 indicating that Veru is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Eloxx Pharmaceuticals has a beta of -1864.08, meaning that its share price is 186,508% less volatile than the broader market. Comparatively, Veru has a beta of -1.15, meaning that its share price is 215% less volatile than the broader market.

Eloxx Pharmaceuticals has higher earnings, but lower revenue than Veru. Veru is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	2.04	-$5.99M	-$15.29	N/A
Veru	$16.89M	2.76	-$22.73M	-$0.89	N/A

Eloxx Pharmaceuticals currently has a consensus price target of $41.50, suggesting a potential upside of 121.22%. Veru has a consensus price target of $24.50, suggesting a potential upside of 797.44%. Given Veru's higher probable upside, analysts clearly believe Veru is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Eloxx Pharmaceuticals' return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Veru	N/A	-47.58%	-35.83%

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Veru beats Eloxx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Eloxx Pharmaceuticals compare to Cassava Sciences?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Eloxx Pharmaceuticals has higher revenue and earnings than Cassava Sciences. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	2.04	-$5.99M	-$15.29	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Eloxx Pharmaceuticals' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Cassava Sciences	N/A	-58.78%	-36.74%

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Eloxx Pharmaceuticals presently has a consensus target price of $41.50, indicating a potential upside of 121.22%. Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 447.47%. Given Cassava Sciences' higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 4 mentions for Eloxx Pharmaceuticals and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat Eloxx Pharmaceuticals' score of 0.57 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eloxx Pharmaceuticals has a beta of -1864.08, suggesting that its stock price is 186,508% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.7, suggesting that its stock price is 170% less volatile than the broader market.

Summary

Eloxx Pharmaceuticals beats Cassava Sciences on 8 of the 14 factors compared between the two stocks.

Get Eloxx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELOX vs. The Competition

Export

Metric	Eloxx Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.13M	$11.92B	$7.02B	$13.07B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-1.23	779.99	271.00	25.33
Price / Sales	2.04	749.72	583.09	76.83
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	0.28	11.60	12.92	6.25
Net Income	-$5.99M	$2.77B	$3.45B	$347.82M
7 Day Performance	6.77%	0.14%	1.15%	1.08%
1 Month Performance	49.01%	0.06%	1.37%	0.82%
1 Year Performance	N/A	145.15%	62.52%	20.99%

Eloxx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELOX Eloxx Pharmaceuticals	2.8644 of 5 stars	$18.76 -1.6%	$41.50 +121.2%	N/A	$13.13M	$6.36M	N/A	N/A	Earnings Report Short Interest Increase
INCR InterCure	1.349 of 5 stars	$0.96 +0.5%	N/A	-42.2%	$52.49M	$78.47M	32.16	350
SCYX SCYNEXIS	3.8612 of 5 stars	$4.81 -0.6%	$24.00 +399.0%	-19.2%	$48.11M	$20.60M	N/A	60	Positive News Earnings Report Analyst Forecast
KPTI Karyopharm Therapeutics	2.7945 of 5 stars	$2.03 -3.3%	$11.50 +466.5%	-56.6%	$47.59M	$146.07M	N/A	380	News Coverage Earnings Report Analyst Upgrade
VERU Veru	2.205 of 5 stars	$2.74 -1.8%	$23.00 +739.4%	-26.4%	$47.57M	$16.89M	N/A	230	Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELOX) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eloxx Pharmaceuticals (ELOX) Competitors

ELOX vs. INCR, SCYX, KPTI, VERU, and FLNA

How does Eloxx Pharmaceuticals compare to InterCure?

Summary

How does Eloxx Pharmaceuticals compare to SCYNEXIS?

Summary

How does Eloxx Pharmaceuticals compare to Karyopharm Therapeutics?

Summary

How does Eloxx Pharmaceuticals compare to Veru?

Summary

How does Eloxx Pharmaceuticals compare to Cassava Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX vs. The Competition

Eloxx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eloxx Pharmaceuticals (ELOX) Competitors

ELOX vs. INCR, SCYX, KPTI, VERU, and FLNA

How does Eloxx Pharmaceuticals compare to InterCure?

Do analysts recommend ELOX or INCR?

Which has more volatility and risk, ELOX or INCR?

Do institutionals and insiders have more ownership in ELOX or INCR?

Does the media refer more to ELOX or INCR?

Which has better earnings & valuation, ELOX or INCR?

Is ELOX or INCR more profitable?

Summary

How does Eloxx Pharmaceuticals compare to SCYNEXIS?

Is ELOX or SCYX more profitable?

Which has preferable earnings and valuation, ELOX or SCYX?

Which has more risk and volatility, ELOX or SCYX?

Does the media refer more to ELOX or SCYX?

Do insiders & institutionals have more ownership in ELOX or SCYX?

Do analysts recommend ELOX or SCYX?

Summary

How does Eloxx Pharmaceuticals compare to Karyopharm Therapeutics?

Do analysts rate KPTI or ELOX?

Do institutionals and insiders believe in KPTI or ELOX?

Is KPTI or ELOX more profitable?

Which has more risk & volatility, KPTI or ELOX?

Which has stronger valuation and earnings, KPTI or ELOX?

Does the media favor KPTI or ELOX?

Summary

How does Eloxx Pharmaceuticals compare to Veru?

Does the media favor ELOX or VERU?

Which has more risk & volatility, ELOX or VERU?

Which has preferable valuation and earnings, ELOX or VERU?

Do analysts recommend ELOX or VERU?

Is ELOX or VERU more profitable?

Do institutionals and insiders hold more shares of ELOX or VERU?

Summary

How does Eloxx Pharmaceuticals compare to Cassava Sciences?

Which has preferable earnings & valuation, ELOX or FLNA?

Is ELOX or FLNA more profitable?

Do insiders & institutionals believe in ELOX or FLNA?

Do analysts rate ELOX or FLNA?

Does the media favor ELOX or FLNA?

Which has more risk & volatility, ELOX or FLNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELOX vs. The Competition

Eloxx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools